This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Zonisamide

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20231004

Version

7

Spl Product Data Elements

Zonisamide Zonisamide ZONISAMIDE ZONISAMIDE FD&C BLUE NO. 1 FD&C RED NO. 4 GELATIN HYDROGENATED COTTONSEED OIL CELLULOSE, MICROCRYSTALLINE SODIUM LAURYL SULFATE TITANIUM DIOXIDE PINK WHITE CAPSULE ZA;31;25;mg Zonisamide Zonisamide ZONISAMIDE ZONISAMIDE FD&C BLUE NO. 1 FD&C RED NO. 4 GELATIN HYDROGENATED COTTONSEED OIL CELLULOSE, MICROCRYSTALLINE SODIUM LAURYL SULFATE TITANIUM DIOXIDE PINK WHITE CAPSULE ZA;32;50;mg Zonisamide Zonisamide ZONISAMIDE ZONISAMIDE FD&C BLUE NO. 1 FD&C RED NO. 4 GELATIN HYDROGENATED COTTONSEED OIL CELLULOSE, MICROCRYSTALLINE SODIUM LAURYL SULFATE TITANIUM DIOXIDE PINK WHITE CAPSULE ZA;33;100;mg

Application Number

ANDA077625

Brand Name

Zonisamide

Generic Name

Zonisamide

Product Ndc

70771-1142

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1142-1 in bottle of 100 Capsules Zonisamide Capsules, 25 mg R x only 100 Capsules NDC 70771-1143-1 in bottle of 100 Capsules Zonisamide Capsules, 50 mg R x only 100 Capsules NDC 70771-1144-1 in bottle of 100 Capsules Zonisamide Capsules, 100 mg R x only 100 Capsules Zonisamide Capsules, 25 mg Zonisamide Capsules, 50 mg Zonisamide Capsules, 100 mg

Spl Medguide

Manufactured by: Cadila Healthcare Ltd. India

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.